Oprelvekin (DrugBank: Oprelvekin)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 288 | 自己免疫性後天性凝固因子欠乏症［自己免疫性出血病XIII (~2017.3)］ | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00994929 (ClinicalTrials.gov) | January 2010 | 12/10/2009 | Efficacy and Safety of IL-11 in DDAVP Unresponsive | Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP | Hemophilia A;Von Willebrand Disease | Biological: Neumega (Oprelvekin, Interleukin 11, IL-11) | University of Pittsburgh | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | United States |
| 2 | NCT00524225 (ClinicalTrials.gov) | February 2008 | 31/8/2007 | IL-11 in Adults With Von Willebrand Disease Undergoing Surgery | Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery | Von Willebrand Disease | Drug: Neumega (Oprelvekin, Interleukin 11, IL-11) | Margaret Ragni | University of North Carolina;Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | 18 Years | N/A | All | 3 | Phase 2 | United States |
| 3 | NCT00524342 (ClinicalTrials.gov) | January 2008 | 31/8/2007 | IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia | Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia | Von Willebrand Disease | Drug: Oprelvekin, Interleukin 11, IL-11 | Margaret Ragni | University of North Carolina;Wyeth is now a wholly owned subsidiary of Pfizer | Completed | 18 Years | 45 Years | Female | 7 | Phase 2 | United States |